Screening for diabetes and prediabetes: the newest communication opportunities

Authors

DOI:

https://doi.org/10.18370/2309-4117.2021.62.92-95

Keywords:

type 2 diabetes mellitus, prediabetes, screening, online questionnaire

Abstract

Type 2 diabetes mellitus (DM-2) and prediabetes are serious diseases that can lead to early disability and death. DM-2 can remain undiagnosed for many years; therefore, screening is one of the main assistants of a doctor in establishing a diagnosis, allowing to start treatment as early as possible.
Research objective: early identification of patients with prediabetes and DM-2 using an online questionnaire.
Materials and methods. The study was carried out online using the Google Forms platform, where a questionnaire was created based on Appendix 3 “Form of risk assessment of diabetes mellitus-2” of the Unified clinical protocol of primary and secondary (specialized) medical care “Type 2 diabetes mellitus”, approved by order of the Ministry of Health of Ukraine No. 1118 dated 12.21.2012, as well as additional questions on nutrition and physical activity. As of June 2021, the study involved 209 patients (151 women and 58 men) who did not have a documented diagnosis of DM-2 or prediabetes.
Results. Most of the respondents (89 people) were overweight. 51 respondents had grade I obesity, 31 respondents had grade II, and 7 patients had a body mass index > 40 kg/m2, which corresponds to grade III obesity. Only 49 respondents had a healthy weight, which corresponds to a body mass index 18.5–24.9 kg/m2. 29 (19.21%) women had a history of childbirth with a child weighing more than 4 kg. The diagnosis of polycystic ovary disease (a risk factor for the DM-2) was in 34 (22.52%) women. Upon receipt of laboratory tests, we established a diagnosis of prediabetes in 28 (13.40%) patients, and a diagnosis of DM-2 in 17 (8.13%) people.
Conclusions. It is necessary to search for new opportunities in communicating with patients during the COVID-19 pandemic, one of which is online questionnaires based on regulatory documents.

Author Biographies

V.I. Velychko, Odesa National Medical University, Odesa

MD, professor, head of the Department of Family Medicine, chairman of the Association of Family Medicine of the Odesa Region

V.L. Mykhailenko, Odesa City Health Center, Odesa

PhD, associate professor, chief physician

D.O. Lahoda, Odesa National Medical University, Odesa

Assistant, Department of Family Medicine

G.O. Volokhova, Odesa National Medical University, Odesa

PhD, associate professor, Department of Physiology

S.L. Liashenko, Odesa National Medical University, Odesa

PhD, associate professor, Department of Physiology

References

  1. Khan, M.A.B, Hashim, M.J., King, J.K, et al. “Epidemiology of type 2 diabetes – global burden of disease and forecasted trends.” J Epidemiol Glob Health 10 (2019): 107–11.
  2. Melmed, S. Williams textbook of endocrinology (13th ed.). Philadelphia. Elsevier (2016): 1386.
  3. Baghaei, A., Sarrafzadegan, N., Rabiei, K., et al. “How effective are strategies for non-communicable disease prevention and control in a high risk population in a developing country? Isfahan Healthy Heart Programme.” Arch Med Sci 6.1 (2010): 24–31.
  4. Faramarzi, H., Bagheri, P., Bahrampour, A., Halimi, L. “The comparison of prevalence of diabete and hypertension between rural areas of fars and rural area of EMRO region.” Iran J Endocrinol Metab 13.2 (2011): 157–64.
  5. Salem, Z., Neshat, A., Bagherian, K., et al. “Prevalence of type II diabetes mellitus in over 30 year old population of Rafsanjan city in the year 2000.” J Rafsanjan Univ Med Sci 3.1 (2004): 9–16.
  6. Shah, A.D., Langenberg, C., Rapsomaniki, E., et al. “Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people.” Lancet Diabetes Endocrinol 3.2 (2015): 105–13.
  7. Tancredi, M., Rosengren, A., Svensson, A.-M., et al. “Excess mortality among persons with type 2 diabetes.” N Engl J Med 373.18 (2015): 1720–32.
  8. Zhou, B., Lu, Y., Hajifathalian, K., et al. “Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants.” Lancet 387.10027 (2016): 1513–30.
  9. Jia, W. “Standardising HbA1c-based diabetes diagnosis: opportunities and challenges.” Expert Rev Mol Diagn 16.3 (2016): 343–55.
  10. Ghaem, H., Daneshi, N., Riahi, S., Dianatinasab, M. “The prevalence and risk factors for diabetic retinopathy in Shiraz, Southern Iran.” Diabetes Metab J 42.6 (2018): 538–43.
  11. Ekoe, J.-M., Goldenberg, R., Katz, P. “Screening for diabetes in adults.” Can J Diabetes 42 (2018): S16–9.
  12. Harris, M.I., Klein, R., Welborn, T.A., Knuiman, M.W. “Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis.” Diabetes Care 15.7 (1992): 815–9.
  13. Porta, M., Curletto, G., Cipullo, D., et al. “Estimating the delay between onset and diagnosis of type 2 diabetes from the time course of retinopathy prevalence.” Diabetes Care 37.6 (2014): 1668–74.
  14. Papatheodorou, K., Banach, M., Edmonds, M., et al. “Complications of diabetes.” Hindawi (2015). Available from: [https://doi.org/10.1155/2015/189525].
  15. Pirart, J. “Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (author's transl).” Diabete Metab 3 (1977): 97.
  16. Pirart, J. “Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (2nd part) (author's transl).” Diabete Metab 3 (1977): 173.
  17. Pirart, J. “Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (3rd and last part) (author's transl).” Diabete Metab 3 (1977): 245.
  18. American Diabetes Association. “Our 60-second type 2 diabetes risk test.” Available from: [https://www.diabetes.org/risk-test], accessed Sep 03, 2020.
  19. Centers for Disease Control and Prevention. “Prediabetes risk test.” Available from: [https://www.cdc.gov/diabetes/risktest/index.html], accessed Sep 03, 2020.
  20. Selvin, E., Wang, D., Matsushita, K., et al. “Prognostic implications of single-sample confirmatory testing for undiagnosed diabetes: a prospective cohort study.” Ann Intern Med 169 (2018): 156.
  21. U.S. Preventive Services Task Force. “Final Recommendation Statement. Prediabetes and Type 2 Diabetes: Screening.” Available from: [https://www.uspreventiveservicestaskforce. org/uspstf/recommendation/screening-for-prediabetes-and-type-2-diabetes#fullrecommendationstart], accessed Oct 08, 2021.
  22. Canadian Task Force on Preventive Health Care. “Recommendations on screening for type 2 diabetes in adults.” CMAJ 184 (2012): 1687.
  23. Centers for Disease Control and Prevention. “Diabetes Risk Factors.” Available from: [https://www.cdc.gov/diabetes/basics/risk-factors.html], accessed Feb 07, 2019.
  24. National Institute for Health and Care Excellence. “Type 2 diabetes: prevention in people at high risk. Public health guideline.” Available from: [https://www.nice.org.uk/guidance/ph38/chapter/Recommendations], аccessed Feb 07, 2019.
  25. Centers for Disease Control and Prevention. “Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic.” Available from: [https://www.cdc.gov/coronavirus/2019-nCoV/hcp/infection-control.html], accessed Dec 29, 2020.
  26. World Health Organization. “Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected.” Available from: [https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125], accessed June 30, 2020.
  27. Lynch, J.B., Davitkov, P., Anderson, D.J., et al. “Infectious Diseases Society of America guidelines on infection prevention for health care personnel caring for patients with suspected or known COVID-19.” Available from: [https://www. idsociety.org/globalassets/idsa/practice-guidelines/covid-19/infection-prevention/idsa-covid-19-guideline_ip_version-1.0.pdf], accessed Apr 29, 2020.

Downloads

Published

2021-12-29

How to Cite

Velychko, V., Mykhailenko, V., Lahoda, D., Volokhova, G., & Liashenko, S. (2021). Screening for diabetes and prediabetes: the newest communication opportunities. REPRODUCTIVE ENDOCRINOLOGY, (62), 92–95. https://doi.org/10.18370/2309-4117.2021.62.92-95

Issue

No. 62 (2021)

Section

Endocrinology

License

Copyright (c) 2021 В.І. Величко, В.Л. Михайленко, Д.О. Лагода, Г.О. Волохова, С.Л. Ляшенко

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.